Andrew Mullen
Medical device company Creavo Medical Technologies has appointed its operations director Andrew Mullen to its Board of Directors, which will see him lead on research and development (R&D) and regulatory affairs. A press release reports that Mullen has held the operator directors at Creavo for over a year, where he advised the board on regulatory matters and product development. It adds that he has been formally appointed to the board in preparation for the company’s next regulatory phase and ahead of commercialisation of its portable magneto-cardiography (MCG) device Corsens in the EMEA region.
Prior to joining Creavo in 2018, Andrew brought over 18 years’ experience in senior operational roles. Most recently, he held the role of group operations director for global radiotherapy business Xstrahl where he was responsible for manufacturing, customer service, and quality and regulatory activities covering the UK, Germany and North American business units.
Steve Parker, CEO of Creavo, says “Andrew’s experience and leadership will be vital in ensuring that we rigorously follow our roadmap for the development of Corsens, which involves moving from product development to full-scale manufacturing ahead of commercialisation. R&D will be focused on ensuring the device is as user-friendly as possible within its intended emergency department setting, where we see it playing a transformative role in the rule out of acute coronary syndromes.”
Creavo Medical Technologies Ltd is a UK-based medical device company that is, according to the press release, developing innovative diagnostic technologies. Creavo’s first application of its technology has the potential to meet an urgent clinical need in global cardiology to help physicians more accurately “rule out” heart-related problems at the point of admission to emergency departments. Its medical device, Corsens, is a battery-powered, portable unit that uses advanced quantum principles to capture, display and process electromagnetic fluctuations caused by heart activity.
